A ``hybrid'' analog which incorporates components of both the AEA-like and dopaminergic neurotransmitter pathways; is nearly inactive as a TRPV1 ligand and fails to elicit hyperalgesic or nocifensive responses in vivo; exhibits an ``entourage'' effect at concentrations of 0.1-10 μM by potentiating the TRPV1-mediated effects of NADA and AEA